NFKB1 and glioblastoma: When GBM cells stably overexpressing CSRP2 were treated with the NF-κB inhibitor JSH 23, cell proliferation (Fig. 5A, B), colony formation (Fig. 5C, D), cell migration (Fig. 5E, F), and cell invasion (Fig. 5G, H) were all reduced.